Post-exposure prophylaxis following high-risk contact with Ebola virus, using immunotherapies with monoclonal antibodies, in the eastern Democratic Republic of the Congo: an emergency use program
Introduction: With the development of therapeutics and vaccine against Ebola virus disease (EVD), the question of post-exposure prophylaxis for high-risk contact has emerged. Immunotherapies (monoclonal antibodies [mAbs]) recently validated for treating infected patients appear to be a good candidate for protecting contacts. Design: During the tenth EVD outbreak in the Democratic Republic of the Congo, we have administrated mAbs (Mab114 or REGN-EB3) to high and intermediate-risk contacts of EVD patients. Results: : Overall, 23 non-vaccinated contacts received mAbs after a median delay between contact and post-exposure prophylaxis of 1 day (interquartile range 1–2). All contacts were free of symptoms, and all had negative reverse transcriptase-polymerase chain reaction 14 days after the contact. Conclusion: Immunotherapies appear to be promising candidates to protect EVD contacts. Interaction with vaccine needs to be analyzed and a larger study on efficacy conducted..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:113 |
|---|---|
| Enthalten in: |
International Journal of Infectious Diseases - 113(2021), Seite 166-167 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Marie Jaspard [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Ebola virus disease |
|---|
| doi: |
10.1016/j.ijid.2021.09.053 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ060603011 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ060603011 | ||
| 003 | DE-627 | ||
| 005 | 20230309003348.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230228s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijid.2021.09.053 |2 doi | |
| 035 | |a (DE-627)DOAJ060603011 | ||
| 035 | |a (DE-599)DOAJebe29c1e543e45a7be5b87f0e0ad9f63 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RC109-216 | |
| 100 | 0 | |a Marie Jaspard |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Post-exposure prophylaxis following high-risk contact with Ebola virus, using immunotherapies with monoclonal antibodies, in the eastern Democratic Republic of the Congo: an emergency use program |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Introduction: With the development of therapeutics and vaccine against Ebola virus disease (EVD), the question of post-exposure prophylaxis for high-risk contact has emerged. Immunotherapies (monoclonal antibodies [mAbs]) recently validated for treating infected patients appear to be a good candidate for protecting contacts. Design: During the tenth EVD outbreak in the Democratic Republic of the Congo, we have administrated mAbs (Mab114 or REGN-EB3) to high and intermediate-risk contacts of EVD patients. Results: : Overall, 23 non-vaccinated contacts received mAbs after a median delay between contact and post-exposure prophylaxis of 1 day (interquartile range 1–2). All contacts were free of symptoms, and all had negative reverse transcriptase-polymerase chain reaction 14 days after the contact. Conclusion: Immunotherapies appear to be promising candidates to protect EVD contacts. Interaction with vaccine needs to be analyzed and a larger study on efficacy conducted. | ||
| 650 | 4 | |a Ebola virus disease | |
| 650 | 4 | |a post-exposure prophylaxis | |
| 650 | 4 | |a monoclonal antibodies | |
| 653 | 0 | |a Infectious and parasitic diseases | |
| 700 | 0 | |a Sylvain Juchet |e verfasserin |4 aut | |
| 700 | 0 | |a Béatrice Serra |e verfasserin |4 aut | |
| 700 | 0 | |a Baweye Mayoum |e verfasserin |4 aut | |
| 700 | 0 | |a Issa Malam Kanta |e verfasserin |4 aut | |
| 700 | 0 | |a Mohamed Seto Camara |e verfasserin |4 aut | |
| 700 | 0 | |a Placide Mbala |e verfasserin |4 aut | |
| 700 | 0 | |a Richard Kojan |e verfasserin |4 aut | |
| 700 | 0 | |a Denis Malvy |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t International Journal of Infectious Diseases |d Elsevier, 2015 |g 113(2021), Seite 166-167 |w (DE-627)DOAJ000043923 |x 18783511 |7 nnns |
| 773 | 1 | 8 | |g volume:113 |g year:2021 |g pages:166-167 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ijid.2021.09.053 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/ebe29c1e543e45a7be5b87f0e0ad9f63 |z kostenfrei |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S1201971221007608 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1201-9712 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 113 |j 2021 |h 166-167 | ||